Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Selina James

Internal Medicine Raleigh, NC Medical Doctor

NPI 1447236781 CMS profile 156259

3200 Blue Ridge Rd, Suite 210, Raleigh, NC 27612

Open in the dashboard

General payments

$6,710

452 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Selina James of Raleigh, NC is reported in the CMS Open Payments database as having received $6,710 across 452 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $465 25
2024 General $802 44
2023 General $880 58
2022 General $1,214 82
2021 General $1,364 93
2020 General $930 67
2019 General $1,055 83

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Selina James
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Selina James were reported at $465. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Selina James Internal Medicine median Middle half National median
2019 $1,055 $159 $48–$570 $163
2020 $930 $119 $33–$402 $114
2021 $1,364 $135 $37–$521 $132
2022 $1,214 $141 $42–$496 $149
2023 $880 $149 $45–$519 $160
2024 $802 $154 $47–$537 $164
2025 $465 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,793 115 payments
  2. Amgen Inc. $732 63 payments
  3. Lilly USA, LLC $522 41 payments
  4. AstraZeneca Pharmaceuticals LP $454 34 payments
  5. AbbVie, Inc. $394 24 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $342 22 payments
  7. Janssen Pharmaceuticals, Inc $232 16 payments
  8. Pfizer Inc. $190 13 payments
  9. Merck Sharp & Dohme Corporation $189 14 payments
  10. Sanofi-Aventis U.S. LLC $186 13 payments
  11. Other $1,676 97 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,691 449 payments
  2. Education $19 3 payments
Products named General payments · program years 2019–2025
  1. Ozempic $1,196 76 payments
  2. RYBELSUS $1,121 71 payments
  3. EVENITY $350 32 payments
  4. Prolia $346 32 payments
  5. FARXIGA $327 25 payments
  6. Repatha $305 27 payments
  7. Wegovy $277 16 payments
  8. JARDIANCE Diabetes $264 20 payments
  9. TRULICITY $247 18 payments
  10. JARDIANCE Diabetes $222 14 payments
  11. Other $5,336 355 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 94 drugs

Part D claims

5,079

Median for Internal Medicine: 777

Drug cost

$344,413

Median for Internal Medicine: $73,373

Branded share of claims

23.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 60 $68,490
Ozempic Semaglutide Brand 49 $63,106
Mounjaro Tirzepatide Brand 37 $37,073
Eliquis Apixaban Brand 22 $27,291
Rybelsus Semaglutide Brand 16 $24,551
Trulicity Dulaglutide Brand 16 $19,455
Xarelto Rivaroxaban Brand 26 $17,521
Synthroid Levothyroxine Sodium Brand 112 $12,611
Myrbetriq Mirabegron Brand 11 $6,347
Rosuvastatin Calcium Generic 380 $5,126

The 10 drugs with the highest cost, of 94 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$85,076

Of which drugs: $19,230

Medicare patients

231

Average age 74

Services billed

1,914

179 women, 52 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 55%
Arthritis 41%
Osteoporosis 22%
Diabetes 18%
Cancer 18%
Ischemic heart disease 14%
Depression 14%
Chronic kidney disease 12%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 18 18 $5,211
Vaccine for influenza for injection into muscle 90653 Office 43 43 $3,436

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $114
$114 — —
RYBELSUS
  • Novo Nordisk Inc $103
$103 16 —
Ozempic
  • Novo Nordisk Inc $103
$103 49 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $48
  • Lilly USA, LLC $22
$70 60 —
NEXLETOL
  • Esperion Therapeutics, Inc. $38
$38 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

452 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record